The $12 million PRIME study will involve 2,000 veterans with major depressive disorder and 250 healthcare providers across 21 VA medical centers.
For the three months ended Sept. 30, the firm reported total revenues of $190.2 million, compared to $177.5 million in Q1 2017, beating the consensus Wall Street estimate.
An international team of researchers examined the scope and population specificity of copy-number variants affecting genes linked to drug metabolism.
Genetic testing can help identify why people aren't responding to certain mental health medications, according to the Philadelphia Inquirer.
Right Patient Right Drug will use the PharmacoScan platform to perform preventive pharmacogenetic testing under St. Jude's PG4KDS program.
Results from a randomized clinical trial known as GIFT suggest that genotype-guided warfarin dosing is linked to fewer adverse events than clinical dosing.
Payors say online, automated systems will bring standardization and efficiency to prior authorizations, but doctors and labs are uncertain about the impact on patient care.
Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.
LifeLabs will analyze patient samples for genetic variations that affect drug response, and will use GenXys' software to inform treatment decisions.
An analysis of six "Implementing Genomics in Practice" (IGNITE) consortium network projects pointed to three main challenges in implementing genomic medicine.
Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.
The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.
CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.
In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.